# A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

> **NCT02611804** · PHASE3 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 492 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Diclofenac sodium
- **DRUG:** Diclofenac sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02611804
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 492 (ACTUAL)
- **Last updated:** 2017-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611804, "A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02611804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*